Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.

BACKGROUND Tenofovir is one of the most widely used antiretroviral drugs. Tenofovir undergoes renal clearance by a combination of glomerular filtration and active tubular secretion. Although rare, the mechanism by which tenofovir causes renal damage is not well characterized. We have explored the association between kidney tubular dysfunction (KTD) and polymorphisms in genes encoding drug transporters. METHODS All consecutive, human immunodeficiency virus (HIV)-infected patients receiving tenofovir-containing antiretroviral regimens who were seen at a single institution during the first trimester of 2008 were enrolled in the study. KTD was defined by the presence of at least 2 of the following abnormalities: nondiabetic glucosuria, urine phosphate wasting, hyperaminoaciduria, beta2-microglobulinuria, and increased fractional excretion of uric acid. Twelve single-nucleotide polymorphisms in the ABCC2, ABCC4, SCL22A6, SLC22A11, and ABCB1 genes were analyzed using TaqMan 5'-nuclease assays. RESULTS A total of 115 HIV-infected patients were examined, of whom 19 (16.5%) had KTD. The percentage of patients with KTD was higher among those with genotype CC at position -24 of ABCC2 than among those with genotypes CT and TT (24% [16 of 68 patients] vs. 6% [3 of 47 patients]; P = .020). In a multivariate analysis, older age (odds ratio [OR], 1.1; 95% confidence interval [CI], 1.0-1.2; P = .024), lower body weight (OR, 0.9; 95% CI, 0.8-0.9; P = .048), and genotype CC at ABCC2 position -24 (OR, 5; 95% CI, 1.2-21; P = .027) were independently associated with KTD. CONCLUSIONS Approximately 17% of HIV-infected patients treated with tenofovir had KTD. Homozygosity for the C allele at position -24 of the ABCC2 gene was strongly associated with KTD in this population. This polymorphism may help to identify patients at greater risk for developing tenofovir-associated tubulopathy, and close monitoring of renal function is warranted for these patients.

[1]  C. Aquilante,et al.  Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients , 2008, Journal of acquired immune deficiency syndromes.

[2]  C. Aquilante,et al.  The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV‐infected Patients , 2008, Clinical pharmacology and therapeutics.

[3]  B. Gazzard,et al.  The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years , 2007, AIDS.

[4]  Yuichi Sugiyama,et al.  Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir , 2007, Molecular Pharmacology.

[5]  Hassane Izzedine,et al.  Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. , 2006, The Journal of infectious diseases.

[6]  K. Robinson,et al.  Mechanism of Active Renal Tubular Efflux of Tenofovir , 2006, Antimicrobial Agents and Chemotherapy.

[7]  J. Brockmöller,et al.  Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. , 2006, British journal of clinical pharmacology.

[8]  G. Rankin,et al.  Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. , 2006, Pharmacology & therapeutics.

[9]  E. De Clercq,et al.  Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  H. Mohrenweiser,et al.  Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6) , 2005, Journal of Pharmacology and Experimental Therapeutics.

[11]  S. Urien,et al.  Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral Therapy , 2005, Antimicrobial Agents and Chemotherapy.

[12]  Hassane Izzedine,et al.  Antiviral drug-induced nephrotoxicity. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  J. Gallant,et al.  Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  F. Russel,et al.  Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. , 2005, American journal of physiology. Renal physiology.

[15]  S. Mauss,et al.  Antiretroviral therapy with tenofovir is associated with mild renal dysfunction , 2005, AIDS.

[16]  M. Perazella,et al.  Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. , 2004, The American journal of medicine.

[17]  V. Soriano,et al.  Tenofovir-related nephrotoxicity in HIV-infected patients. , 2004, AIDS.

[18]  J. Reynes,et al.  Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. , 2004, Journal of acquired immune deficiency syndromes.

[19]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[20]  D. Droz,et al.  Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Rossert,et al.  Fanconi syndrome and renal failure induced by tenofovir: a first case report. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  M. Perazella,et al.  Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. , 2002, The American journal of the medical sciences.

[23]  M. Kasuga,et al.  Significant Genetic Linkage of MDR1 Polymorphisms at Positions 3435 and 2677: Functional Relevance to Pharmacokinetics of Digoxin , 2002, Pharmaceutical Research.

[24]  Miyuki Kimura,et al.  Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein , 2002, Clinical pharmacology and therapeutics.

[25]  F. Russel,et al.  The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. , 2002, Journal of the American Society of Nephrology : JASN.

[26]  D. Miller,et al.  Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. , 2001, The Journal of pharmacology and experimental therapeutics.

[27]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[28]  T. Cihlar,et al.  NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 641–648 (2001) HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGS , 2003 .

[29]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.